Transplant Creations1 Treatment & Transplant Program to improve disease outcome Transplant Creations Marlies Van Hoef.

Slides:



Advertisements
Similar presentations
Pediatric Cancer & Leukemia December 4, Pediatric Oncology  Acute leukemia  Brain tumors  Lymphoma  Neuroblastoma  Wilm’s tumor  Rhabdomyosarcoma.
Advertisements

Hematopoietic stem cell transplantation
Blood and marrow stem cell transplantation A.Basi ADULT HEMATOLOGIST,ONCOLOGIST IRAN UNIVERSITY OF MEDICAL SCIENCES.
Hematopoietic Stem Cell Transplantation (HSCT) Overview Willis H Navarro, MD Medical Director, Transplant Services, NMDP Associate Clinical Professor,
CHIMERISM & DLI Dr. Serdar ŞIVGIN Kayseri Feb, 2011.
Jeffrey Schriber, M.D. FRCP (c) Medical Director Cancer Transplant Institute Virginia G. Piper Cancer Center Everything You Ever Wanted to Know About Transplant.
LaCasce A et al. Proc ASH 2014;Abstract 293.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2011 Summary Slides Worldwide SUM-WW11_1.ppt.
What is Leukemia? Leukemia is cancer of the blood. Often times, symptoms of Leukemia go unnoticed or do not appear at all in the early stages. Because.
The acute Leukemias are clonal hematopoietic malignant disease that arise from the malignant T r a n s f o r m a t i o n of an early Hematopoietic stem.
DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN.
Treatment of Non- Hodgkin’s Lymphoma. Precursor B cell Lymphoblastic Leukemia Remission induction with combination therapy Consolidation phase: –High.
MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.
Multiple Myeloma Definition:
5-Azacitidine For Myelodysplasia Before Allogeneic Hematopoietic Cell Transplantation Field T et al. Bone Marrow Transplant 2009:[Epub ahead of print].
DONOR LYMPHOCYTE INFUS I ON (DLI) Dr. Serdar ŞIVGIN February 2011 Kayseri.
Allogeneic “Mini” Transplantation Mark B. Juckett M.D. June 4, 2004.
Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed/Refractory Hodgkin Lymphoma (HL) in the Brentuximab.
Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.
DLBCL with less than PR to second line therapy… Correcting a Misconception…. Koen van Besien, MD Weill Cornell Medical College, NY.
Neuroblastoma.
Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.
Due to the non-myeloablative nature of the reduced intensity conditioning, following infusion there is a period of mixed-chimerism with both patient and.
Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.
Abstract Immune Reconstitution and Clinical Outcome After Donor Lymphocyte Infusion for Relapsed Disease After Reduced-Intensity Allogeneic Hematopoietic.
Hematopoietic Stem Cell Transplantation (HSCT)
The impact of age on outcome in early-stage breast cancer 방사선종양학과 R2. 최진현.
Margaret L. Green, Wendy M. Leisenring, Hu Xie, Roland B. Walter, Marco Mielcarek, Brenda M. Sandmaier, Stanley R. Riddell and Michael Boeckh Blood NUM.
New Approaches for Transplant Patients Linda J Burns, MD Medical Director, Health Services Research Program National Marrow Donor Program (NMDP)/Be the.
Stem Cell Transplantation
Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation  Nirali N. Shah, Michael J. Borowitz,
Slamon D et al. SABCS 2009;Abstract 62.
Vose JM et al. Proc ASH 2011;Abstract 661.
Palumbo A et al. Proc ASH 2012;Abstract 200.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation
Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides INTRODUCTION: The Summary Slides are an annual report.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation
The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk.
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
Il trapianto allogenico da donatore alternativo dopo condizionamento a ridotta intensità Alessandro Rambaldi.
The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.
Ematologia, Ospedali Riuniti, Bergamo
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.
Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI  Alix O’Meara, Jörg Halter, Dominik.
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION for MULTIPLE MYELOMA
Introduction Case Report Conclusion
Reduced-Intensity Allogeneic Stem Cell Transplantation in Adults and Children with Malignant and Nonmalignant Diseases: End of the Beginning and Future.
Grövdal M et al. Blood 2008;112:Abstract 223.
Hematopoietic Stem Cell Transplantation for Patients with AML
Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease–Guided Multiple DLIs Could Improve Outcomes.
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
Practical Radiation Oncology
Allogeneic Transplantation for Pediatric Acute Lymphoblastic Leukemia: The Emerging Role of Peritransplantation Minimal Residual Disease/Chimerism Monitoring.
Presented by: Dr.Naser Shagerdi Esmaeli
High Alloreactivity of Low-Dose Prophylactic Donor Lymphocyte Infusion in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation  Rachel B. Salit, Filippo.
Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.
Mohamed L. Sorror, MD, MSc ASH Oral presentation December 2018
Clinical Lymphoma, Myeloma and Leukemia
Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation  Nirali N. Shah, Michael J. Borowitz,
Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer.
Timing for HCT Consultation
Mary Eapen  Biology of Blood and Marrow Transplantation 
Protocol description (randomized phase).
by Lapo Alinari, and Kristie A. Blum
Autologous Stem Cell Transplantation for POEMS Syndrome
Presentation transcript:

Transplant Creations1 Treatment & Transplant Program to improve disease outcome Transplant Creations Marlies Van Hoef

Transplant Creations2 Introduction In the late 90s non-myeloablative allogeneic stem cell transplantation (NMT) gained interest because the procedure is associated with less treatment-related side effects than ablative allogeneic stem cell transplantation The improved tolerability offers the opportunity to integrate NMT as part of initial treatment. Implementation at this time offers to improve disease outcome Transplant Creations program supports that goal

Transplant Creations3 Breast Cancer Introduction At the end of the 90s high-dose autologous transplants for breast cancer had received (unjust) negative press In the adjuvant setting though, a trend towards improvement of disease free survival was suggested in premenopausal women, TRM varied with the regimen An allogeneic immune response had been reported

Transplant Creations4 Non-myeloablative Transplant Programs Protocols Program NMT for early stage disease NMT for relapse after prior autologous transplant Goal Enhance collaboration Opportunities for patients and investigators Multi-center NMT development Improve cure rates and survival

Transplant Creations5 NMT for early Stage Disease At diagnosis: Dose intensive induction chemotherapy Two semi-high-dose autologous transplants or equivalent in leukemia A non-myeloablative reduced intensity conditioning allogeneic transplant

Transplant Creations6 NMT for early Stage Disease indications Acute leukemia Chronic leukemia Multiple myeloma (Non-)Hodgkin lymphoma Neuroblastoma Breast cancer

Transplant Creations7 NMT for relapse after prior autologous Transplant Compassionate use program in case at initial diagnosis no donor could be timely found The risks of treatment are increased The likelihood of survival is decreased compared to integration in the strategy from initial diagnosis We disrecommend use as the costs do in general not outweight the benefits

Transplant Creations8 Invitation For information contact or.org

Transplant Creations9 Contact For our services and protocols contact us: For eligibility checks contact us: